![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Catco Reinsurance Opportunities Fund Limited | LSE:CAT | London | Ordinary Share | BMG1961Q3242 | ORD USD0.00013716 (DI) |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 24.00 | 13.00 | 35.00 | 24.00 | 24.00 | 24.00 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Unit Inv Tr, Closed-end Mgmt | 6.33M | 5.44M | 3.6440 | 6.59 | 35.84M |
RNS Number:2290X Cambridge Antibody Tech Group PLC 15 January 2001 For further information contact: Cambridge Antibody Technology Tel: +44 (0) 1763 263233 Diane Mellett, General Counsel John Aston, Finance Director Rowena Gardner, Head of Corporate Communications HCC De Facto (Europe) Tel: +44 (0) 20 7496 3300 Adam Michael David Speechley BMC Communications/The Trout Group (USA) Tel: 001 212 477 9007 Brad Miles, ext.17 (media) Brandon Lewis, ext.15 (investors) CAMBRIDGE ANTIBODY TECHNOLOGY GRANTED FURTHER KEY PATENT IN US Melbourn, UK Cambridge Antibody Technology (LSE: CAT) has announced that it has been granted another US patent, US 6,172,197, entitled "Methods for Producing Members of Specific Binding Pairs". The patent provides protection for libraries of phage displaying functional protein binding domains derived from natural repertoires of nucleic acids, wherein each phage particle contains a phagemid genome. Dependent claims cover display of antibodies, and of scFv or Fab antibody fragments. Dr David Chiswell, CAT's CEO, commented, "This patent further extends CAT's growing US patent estate covering the phage display of antibodies and antibody fragments. It is particularly noteworthy that this new patent includes not just scFv antibody fragments but also Fab antibody fragments as well as other non-antibody proteins. Taken together with CAT's other patents granted worldwide, the granting of this patent reinforces the strength of CAT's patent position and confirms CAT's leadership in the development of human antibodies." Notes to Editors: Cambridge Antibody Technology (LSE: CAT) CAT is a UK biotechnology company using its proprietary technologies in human monoclonal antibodies for drug discovery and drug development. Based in Melbourn, 10 miles south of Cambridge, England, CAT currently employs nearly 200 people. CAT is listed on the London Stock Exchange, having raised #41m in its IPO in March 1997. A secondary offering in March 2000 raised #93m. CAT has a world-leading platform technology for rapidly isolating human monoclonal antibodies using phage display systems. CAT has an extensive phage display antibody library, currently incorporating around 100 billion distinct antibodies. This library forms the basis for the company's strategy to develop a portfolio of clinical development programs and for discovering new drug leads using functional genomics. Four fully human therapeutic antibodies developed by CAT are at various stages of clinical trials. CAT works in partnership with other companies at all stages of the drug discovery and development process. CAT's collaborations, past and present, include: AstraZeneca, BASF Pharma, Eli Lilly, Genentech, Genetics Institute, Genzyme, Human Genome Sciences, Immunex, Oxford GlycoSciences, Pharmacia Corporation, Pfizer, Wyeth-Ayerst CAT's patent portfolio CAT's patent portfolio broadly covers the field of phage display of antibodies and, along with the licences CAT has (particularly with The MRC, Dyax, Scripps and Stratagene), gives CAT the freedom to operate its technology. CAT currently has two main patent families covering antibody libraries (Winter II) and phage display (McCafferty). CAT's Winter II and McCafferty patents have both been granted in Europe (9 April 1994 and 13 November 1996 respectively). The granted US McCafferty continuation is entitled to a term expiring on 19 October 2016. The Griffiths et al patent (US 5,885,793) was granted on 23 March 1999. It refers to the isolation of human antibodies to human proteins by phage display and to methods for producing human antibodies. Phagemids A phagemid is a plasmid containing a bacterial origin of replication and a phage origin of replication. Use of a phagemid containing a geneIII-antibody fusion, together with a helper phage, allows a mixture of wild-type pIII and fusion pIII to be displayed on the surface of the phage particle. If phagemids are not used, several antibody molecules are displayed on each phage (multivalent display). Phagemids allow display of a single antibody molecule per phage (monovalent display) enabling selection for higher affinity antibodies by avoidance of avidity effects. The phagemid system is widely used by antibody phage display companies. Fab A Fab fragment is a two chain fragment of an antibody molecule containing the binding site for antigens, such as human proteins. It consists of two chains, the light chain and the part of the heavy chain including the antigen binding region. Fab fragments are widely used by phage display companies. scFv A scFv fragment is a single chain molecule containing the binding site of an antibody molecule for antigens such as human proteins. It consists of part of the light chain and part of the heavy chain including the antigen binding region, linked together into a single molecule. ScFv molecules are widely used by phage display companies.
1 Year Catco Reinsurance Opport... Chart |
1 Month Catco Reinsurance Opport... Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions